What Does Not Affect Surgical Outcomes in NSCLC? : vimarsana

AEGEAN is one of the first studies of immune checkpoint inhibitors in the perioperative settings to demonstrate improved EFS and pCR with no effect on surgical outcomes.

Related Keywords

Switzerland , Tetsuya Mitsudomi , Solange Peters , Astrazeneca , Bristol Myers Squibb , University Hospital Of Lausanne , World Conference , Lung Cancer , University Hospital , Ung Carcinoma , Ancer Lung , Surgery , Neoadjuvant , Non Small Cell Lung Cancer , Nsclc , Perioperative , Pcr , Polymerase Chain Reaction , Small Cell Lung Cancer , Chemotherapy , Combination Chemotherapy , Tumor , Biologic Therapy , Cancer , Alignant Neoplasia , Arcinoma , Lung , Presection , Lymph Node Dissection ,